Trial intelligence / Profile preview

Flu-M Vaccine in Children (6 Months to 9 Years)

NCT05470582Phase 3Completed

Sponsor
Saint Petersburg Scientific Research Institute of Vaccines and Serums
Start
Feb 2021
Primary completion
Oct 2021
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza, sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Started Feb 2021; status: completed.

02

Drugs

Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03

Conditions

influenza

Beyond the preview

Go deeper on NCT05470582.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05470582.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call